– With prize money of one million euros, the Broermann Medical Innovation Award is one of the highest -payer medical prices in the world
-Award for pioneering pioneering work in the field of cancer therapy using Car-T cells
– Ceremony by the Hessian Prime Minister Boris Rhein
The jury of the Broermann Medical Innovation Award (BMIA) draws Dr. Carl June (University of Pennsylvania) and Dr. Michel Sadelain (Columbia University) for her pioneering research work in the field of car-t cell therapy. The BMIA will be awarded for the first time this year. With a doping of one million euros, the price is one of the highest -doped awards for medical research worldwide.
A revolution in cancer therapy
Dr. Carl June (71) and Dr. Michel Sadelain (65) are recognized for her role in the genetic manipulation of T cells that attack and eliminate cancer cells. To do this, use synthetic receptors, so -called chimeric antigen receptors (chimeric antigen receptors – cars) that enable the T cells to recognize and destroy cancer cells. Car-T cells achieve amazing success rates in types of cancer such as leukemia, lymphomas and myelomas; In the case of other types of cancer, this new approach is in the test phase. Through their groundbreaking work, June and Sadelain have opened a completely new chapter in cancer therapy.
Dr. Carl June, Richard W. Vague Professor in Immunotherapy at the University of Pennsylvania, says: “I feel very honored to get the first Broermann Medical Innovation Award together with my appreciated colleague Michel Sadelain. This award not only honors our decades of research, but above all the transformative potential of car-cell therapy for Cancer patients worldwide. “
Dr. Michel Sadelain, director of the Columbia Initiative in Cell Engineering and Therapy (Cicet), says: “The awarding of the Broermann Medical Innovation Award for me is an extraordinary honor and recognition for the revolutionary power of car-t cell therapy. Together with Carl June, we have worked on transforming the immune system into a precise weapon against cancer. What the Broermann Award stands for: medical breakthroughs that fundamentally change the life of patients.
Selection process of the renowned jury
The winners of the Broermann Medical Innovation Award are selected by a scientifically outstanding jury who is composed of nine high -ranking members of renowned institutes: Prof. Dr. Werner Seeger (Chair of the Broermann Medical Innovation Award), Prof. Dr. Karsten Krüger (member of the Presidium of the Justus Liebig University Gießen), Prof. Dr. Isabelle Bekeredjian-thing (director of the Center for Infection, Inflammation and Immunity of the University of Marburg), Prof. Dr. Britta Siegmund (Vice President of the German Research Foundation), Prof. Dr. Stefan Offermanns (director of the Max Planck Institute for Heart and Lung Research), Prof. Dr. Otmar Wiestler (President of the Helmholtz Community), Prof. Dr. Dr. Gerd Geißlinger (director of the Fraunhofer Institute for Clinical Pharmacology), Prof. Dr. Martina Brockmeier (President of the Leibniz Community), Dr. Jan Liersch (Managing Director of Broermann Holding GmbH). Supported by a circle of international experts: Inside, the committee checks all nominations in a multi -stage process that guarantees the highest scientific quality and independence. The decision is based on strict selection criteria.
To the award winners
Dr. Carl June was born in Denver, USA in 1953. He received his doctorate at the Baylor College of Medicine in Houston, Texas, and received his PhD at the Fred Hutchinson Cancer Research Center in Seattle. After a scientific career in Navy, June founded the Center for Cellular Immunotherapies (CCI) at the University of Pennsylvania in Philadelphia in 1999 and built an interdisciplinary research platform for cellular immunotherapies. He received the renowned Richard W. Vague professorship there in 2012.
Dr. Michel Sadelain was born in Paris, France, in 1960 and received a doctorate at the University of Paris in 1984. He received his PHD in 1989 at the University of Alberta, Canada, and then researched as a postdoc at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology (with). In 1994 he moved to the Memorial Sloan Kettering Cancer Center in New York. Sadelain is currently the director of the “Columbia Initiative in Cell Engineering and Therapy (Cicet)” in New York, founded in 2024, and leads innovative cell therapy concepts there.
To date, the two scientists have been awarded numerous scientific prices for their groundbreaking research and performance in cancer therapy.
Premiere des Broermann Medical Innovation Award
The Broermann Medical Innovation Award was made by Dr. Bernard Große Broermann, namesake and founder of the Asklepios clinics. Dr. Great Broermann from the vision of creating an innovative healthcare company that creates real benefits for people. Under his leadership, Asklepios set standards in medical innovation, invested specifically in the latest medical technology and digital solutions and thus promoted progress in patient care – values that are also based on the Broermann Medical Innovation Award. With the price, his vision continues and underlines the commitment that continues in his foundation beyond his lifetime. The price is endowed with a record amount of 1 million euros. The ceremonial award takes place in the Hessian State Chancellery in Wiesbaden, the prize is presented by the Hessian Prime Minister Boris Rhein.